Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1Classical hematology 1

Conditions

Multiple Myeloma 3Lymphoma 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Sarcoma 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2fludarabine 2Sorafenib 2Oxaliplatin 2Leucovorin 2Interleukin-2 2Fluorouracil 2Denosumab 2Bortezomib 2Bevacizumab 2venetoclax 1vactosertib 1trametinib 1temsirolimus 1sargramostim 1ruxolitinib 1repotrectinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1enzalutamide 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Dalteparin × Plasma cell × Clear all
NCT00525057 2021-01-22

Dalteparin in Preventing DVT in Participants With Cancer

M.D. Anderson Cancer Center

Phase NA Completed
65 enrolled 14 charts
LymphoidPlasma cellSarcoma

Bone Neoplasms, Femoral Fractures, Fractures, Spontaneous, Lymphoma, Multiple Myeloma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡